Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: Results of a multicentric study

Autoimmunity Reviews

Volumn 10, Issue 9, 2011, Pages 509-513

  Ghillani, P ^a,b   Andre C ^b   Toly, C ^b   Rouquette, A M ^b   Bengoufa, D ^b   Nicaise, P ^b   Goulvestre, C ^b   Gleizes, A ^b   Dragon Durey, M A ^b   Alyanakian, M A ^b   Chretien, P ^b   Chollet Martin, S ^b   Musset, L ^a,b   Weill, B ^b   Johanet, C ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Groupe Hospitalier Avicenne Jean Verdier Rene Muret   (France)

Author keywords

Anti Ro52 (TRIM21) antibodies; Autoimmune diseases; Interstitial lung disease; TRNA antisynthetase syndrome

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE; ANTIBODY; CENTROMERE PROTEIN B; JO 1 ANTIBODY; RO52 ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTISYNTHETASE SYNDROME; AUTOIMMUNE HEPATITIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CHROMATIN; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DERMATOMYOSITIS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LABORATORY; LUNG CANCER; LUNG FIBROSIS; LUPUS VULGARIS; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PREVALENCE; PULMONARY HYPERTENSION; REVIEW; SERUM; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; RIBONUCLEOPROTEINS; YOUNG ADULT;

EID: 79957906242     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.03.004     Document Type: Review

References (36)

1. Schulte-Pelkum J., Fritzler M., Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009, 8:632-637.
2. Ben Chetrit E., Chan E.K.L., Sullivan K.F., Tan E.M. A 52-kD protein is a novel component of the SS-a/Ro antigenic particle. J Exp Med 1988, 167:1560-1571.
3. Chan E.K., Hamel J.C., Buyon J.P., Tan E.M. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest 1991, 87:68-76.
4. Frank M.B., Itoh K., Fujisaku A., Pontarotti P., Mattei M.J., Neas B.R. The mapping of the human 52-kD Ro/SSA autoantigen gene to human chromosome 11, and its polymorphisms. Am J Hum Genet 1993, 52:183-191.
5. Rhodes D.A., Ihrke G., Reinicke A.T., Malcherek G., Towey M., Isenberg D.A., et al. The 52000MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology 2002, 106:246-256.
6. Wada K., Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 2006, 339:415-421.
7. Rhodes D.A., Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol Immunol 2007, 44:2406-2414.
8. Burbelo P., Ching K., Han B., Bush E., Reeves W., Iadarola M. Extraordinary antigenicity of the human Ro52 autoantigen. Am J Trans Res 2010, 2:145-155.
9. Defendenti C., Atzeni F., Spina M.F., Grosso S., Cereda A., Guercilena G., et al. Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. Autoimmun Rev 2011, 10:150-154.
10. Rutjes S.A., Jongen P., Van Dem H.F., Pruijn G.J., van Venrooij W.J. Anti-Ro52 antibodies frequently co-occur with anti-Jo1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997, 109:32-40.
11. Granito A., Muratori P., Muratori L., Pappas G., Cassani F., Worthington J., et al. Antibodies to SS-A/Ro52 kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007, 26:831-838.
12. Eyraud V., Chazouillières O., Ballot E., Corpechot C., Poupon R., Johanet C. Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 2009, 29:857-864.
13. Hervier B., Rimbert M., Colonna F., Hamidou M.A., Audrain M. Clinical significance of anti-Ro/SSA-52kDa antibodies-a retrospective monocentric study. Rheumatology 2009, 48:964-967.
14. Langguth D.M., Morris S., Clifford L., Wilson R.J., Neil J., Hogan P.G., et al. Specific testing for "isolated" anti-52kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen testing is of limited clinical value. J Clin Pathol 2006, 60:670-673.
15. Verstegen G., Duyck M.C., Meeus P., Ravelingien I., De Vlam K. Detection and identification of antinuclear antibodies (AAN) in a large community hospital. Acta Clin Belg 2009, 64:317-323.
16. Peene I., Meheus L., Keyser S., Humbel R., Veys E.M., De Keyser F. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 2002, 61:929-933.
17. Arbuckle M.R., McClain M.T., Rubertone M.B., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
18. Song JS, Do JH, Lee SW. The prevalence and the clinical relevance of anti-Ro52 in Korean patients with primary Sjögren's syndrome. Rheumatol Int 2011 (Jan 19, Electronic publication ahead of print).
19. Liaskos C., Bogdanos D.P., et al. Antibody responses specific for soluble liver antigen co-occur with Ro52 autoantibodies in patients with autoimmune hepatitis. J Hepatol 2009, (Suppl. 1):250.
20. Locht H., Pelck R., Manthorpe R. Diagnostic and prognostic significance of measuring antibodies to alpha-fodrin compared to anti-Ro-52, anti-Ro60, and anti-La in primary Sjögren's syndrome. J Rheumatol 2008, 35:845-849.
21. Jaeggi E., Laskin C., Hamilton R., Kingdom J., Silverman E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus. A prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010, 55:2778-2784.
22. Eftekhari P., Sallé L., Lezoualc'h F., Mialet J., Gastineau M., Briand J., et al. Anti-SSA/Ro52 antibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block. Eur J Immunol 2000, 30:2782-2790.
23. Fritsch C., Hoebeke J., Dali H., Ricchiuti V., Isenberg D.A., Meyer O., et al. 52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. Arthritis Res Ther 2006, 8:R4.
24. Cuneo B.F., Fruitman D., Benson D.W., Ngan B.Y., Liske M.R., Wahren-Herlineus M., et al. Spontaneous rupture of atrioventricular valve tensor apparates as late manifestation of Anti-Ro/SSA antibody-mediated cardiac disease. Am J Cardiol 2011, 107:761-766.
25. Espinosa A., Zhou W., Ek M., Hedlund M., Brauner S., Popovic K., et al. The Sjögren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 2006, 176:6277-6285.
26. Oke V., Vassilaki I., Espinosa A., Stranberg L., Kuchroo V., Nyberg F., et al. High Ro52 expression in spontaneous and UV-induced cutaneous inflammation. J Invest Dermatol 2009, 129:2000-2010.
27. Suber T.L., Casciola-Rosen L., Rosen A. Mechanisms of disease: autoantigen as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol 2008, 4:201-209.
28. Gomez-Martin D., Diaz-Zamudio M., Alcocer-Varela J. Ubiquitination system and autoimmunity: the bridge towards the modulation of the immune response. Autoimmun Rev 2008, 7:284-290.
29. Mallery D.L., McEwan W.A., Bidgood S.R., Towers G.J., Johnson C.M., James L.C. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). PNAS 2010, 46:19985-19990.
30. Parker J., Burlingame R., Bunn C. Prevalence of antibodies to Ro-52 in a serological defined population of patients with systemic sclerosis. J Autoimmune Dis 2009, 6:2.
31. Dugar M., Cox S., Limaye V., Gordon T.P., Roberts-Thomson P. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010, 86:79-82.
32. La Corte R., La Mo Naco A., Locaputo A., Dolzani F., Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial Lung disease. Autoimmunity 2006, 39:249-253.
33. Levine S.M., Raben N., Xie D., Askin F.B., Tuder R., Mullins M., et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum 2007, 56:2729-2739.
34. Sibilia J., Chatelus E., Meyer A., Gottenberg J.E., Sordet C., Goetz J. How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies. Presse Med 2010, 39:1010-1025.
35. Strandberg L., Ambrosi A., Espinosa A., Ottosson L., Eloranta M.L., Zhou W., et al. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J Clin Immunol 2008, 28:220-231.
36. Espinosa A., Dardalhon V., Brauner S., Ambrosi A., Higgs R., Quintana F., et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009, 8:1661-1671.